BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 1786476)

  • 1. Inactivation of viruses found with plasma proteins.
    Horowitz B
    Biotechnology; 1991; 19():417-30. PubMed ID: 1786476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific inactivation of viruses which can potentially contaminate blood products.
    Horowitz B
    Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
    Mannucci PM
    Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory and preclinical evaluation of the virus safety of coagulation factor concentrates.
    Horowitz B; Prince AM
    Dev Biol Stand; 1987; 67():291-302. PubMed ID: 3609483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Viruses and unconventional transmissible agents: update on transmission via blood ].
    Barin F
    Transfus Clin Biol; 2000 Jun; 7 Suppl 1():5s-10s. PubMed ID: 10919217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood protein derivative viral safety: observations and analysis.
    Horowitz B
    Yale J Biol Med; 1990; 63(5):361-9. PubMed ID: 1963504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. International Factor Safety Study Group.
    Shapiro A; Abe T; Aledort LM; Anderle K; Hilgartner MW; Kunschak M; Preston FE; Rivard GE; Schimpf K
    Transfusion; 1995 Mar; 35(3):204-8. PubMed ID: 7878711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of virus-free labile blood derivatives--a review.
    Prince AM; Horowitz B; Horowitz MS; Zang E
    Eur J Epidemiol; 1987 Jun; 3(2):103-18. PubMed ID: 3301391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of viruses in blood and plasma products.
    Suomela H
    Transfus Med Rev; 1993 Jan; 7(1):42-57. PubMed ID: 8431658
    [No Abstract]   [Full Text] [Related]  

  • 11. Transfusion-transmitted disease.
    Lee CA
    Baillieres Clin Haematol; 1996 Jun; 9(2):369-94. PubMed ID: 8800511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral safety of solvent/detergent-treated blood products.
    Horowitz B; Prince AM; Hamman J; Watklevicz C
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S21-8; discussion S29-S30. PubMed ID: 7749045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of hepatitis viruses and HIV in plasma and plasma derivatives by treatment with beta-propiolactone/UV irradiation.
    Stephan W
    Curr Stud Hematol Blood Transfus; 1989; (56):122-7. PubMed ID: 2642784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procedures for the inactivation of viruses in clotting factor concentrates.
    Gomperts ED
    Am J Hematol; 1986 Nov; 23(3):295-305. PubMed ID: 3020979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light.
    Lin L; Hanson CV; Alter HJ; Jauvin V; Bernard KA; Murthy KK; Metzel P; Corash L
    Transfusion; 2005 Apr; 45(4):580-90. PubMed ID: 15819680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates.
    Corash L
    Vox Sang; 1998; 74 Suppl 2():173-6. PubMed ID: 9704443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin.
    Horowitz B; Busch M
    Transfusion; 2008 Aug; 48(8):1739-53. PubMed ID: 18466171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral safety of clotting factor concentrates.
    Fricke WA; Lamb MA
    Semin Thromb Hemost; 1993; 19(1):54-61. PubMed ID: 8456324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.
    Tabor E
    Transfusion; 1999; 39(11-12):1160-8. PubMed ID: 10604241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview: diagnostic tests for viral infections transmitted by blood.
    Holland PV
    Nucl Med Biol; 1994 Apr; 21(3):407-17. PubMed ID: 9234305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.